TSR 011

Drug Profile

TSR 011

Alternative Names: TSR-011

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator Amgen
  • Developer TESARO
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 14 Jul 2015 Phase-I/II clinical trials in Solid tumours, Non-small cell lung cancer and Lymphoma in Poland, Spain, Taiwan (PO)
  • 14 Jul 2015 TSR 011 is still in phase I/II trials for Solid tumours, Non-small cell lung cancer and Lymphoma in USA and United Kingdom
  • 03 Jul 2014 TSR 011 is available for licensing worldwide (excluding North America, Europe and China) (http://tesarobio.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top